GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...
The Food and Drug Administration has approved Ozempic ® (semaglutide ... and cardiovascular death in adults with type 2 diabetes mellitus (T2D) and chronic kidney disease (CKD). The approval was based ...
A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans at risk for kidney failure.
Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy ... Those included nausea and vomiting, kidney stones, gastroesophageal reflux disease (GERD), sleep issues ...
Recent studies highlight side effects such as heart muscle weakening and skin hypersensitivity, along with gastrointestinal issues, pancreatitis, and potential kidney damage. Ozempic and other GLP ...